Drug Shortage Report for REVATIO
| Report ID | 181292 |
| Drug Identification Number | 02341611 |
| Brand name | REVATIO |
| Common or Proper name | REVATIO |
| Company Name | BGP PHARMA ULC |
| Market Status | MARKETED |
| Active Ingredient(s) | SILDENAFIL |
| Strength(s) | 0.8MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1 |
| ATC code | C02KX |
| ATC description | OTHER ANTIHYPERTENSIVES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2023-02-06 |
| Estimated end date | 2023-03-28 |
| Actual end date | 2023-02-24 |
| Shortage status | Resolved |
| Updated date | 2023-05-05 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2023-05-05 | French | Compare |
| v4 | 2023-05-05 | English | Compare |
| v3 | 2023-02-07 | English | Compare |
| v2 | 2023-01-17 | French | Compare |
| v1 | 2023-01-17 | English | Compare |
Showing 1 to 5 of 5